Emerald Group Publishing Limited
Copyright © 2008, Emerald Group Publishing Limited
Ablynx extends agreement with Wyeth
Article Type: Food Facts From: Nutrition & Food Science, Volume 38, Issue 3.
GHENT, Belgium, December 20, 2007 Ablynx [Euronext Brussels: ABLX], a pioneer in the discovery and development of Nanobodies®, a novel class of antibody-derived therapeutic proteins, announced today that its TNF-alpha partnership with Wyeth Pharmaceuticals has been extended for another year. Wyeth and Ablynx are collaborating to discover and develop novel Nanobody®-based therapeutics against TNF-alpha. Wyeth has exclusive rights to develop and commercialise the anti-TNF-alpha Nanobodies® developed under the collaboration.